Durham, N.C., April 01, 2026 (GLOBE NEWSWIRE) — Final participant randomized in the GenePHIT Phase 2 clinical trial assessing safety and efficacy of AB-1002 for adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms Initial results are expected in the first half of 2027 Completion of enrollment marks significant…
The post AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure appeared first on Montreal Gazette.
SUNshineGirl Nevada
...
Read moreDetails
